Cardiovascular disease (CVD) is the number one cause of death wordwide1. The cause of CVD is atherosclerosis. Cardiovascular risk does not correlate with clinical symptoms until considerable atherosclerotic* disease progression. Consequently, early accurate CVD risk assessment is part of an established clinical strategy of primary prevention. A number of guidelines have been established for the prevention, diagnosis, evaluation and management of CVD. The goal being the reduction of cardiac events such as acute heart attack (myocardial infarction, MI) and stroke. CVD risk assessment is therefore a key aspect of clinical care for all individuals between the age of 40-79.
Clinical CV risk factors include hypertension, diabetes mellitus, chronic kidney disease, obesity, cigarette smoking and family history. The most important biomarkers for CV risk determination are lipids including total cholesterol, triglycerides, LDL and HDL cholesterol. Early epidemiological studies associated both total cholesterol and LDL cholesterol to CV risk. Current studies have shown that there is discordance in quite a number of individuals based on the standard lipid profile. Thus, the determination of lipoprotein particle (LDL-P) numbers offers a more accurate risk assessment especially in those individuals with other comorbid conditions. A simple determination of total cholesterol with its subgroups HDL and LDL is thus no longer sufficient. As a consequence it is recommended to consult further parameters providing data beyond the conventional lipid panel.
numares offers an on-site technology for the assessment of cardiovascular risk, i.e. an in-depth lipoprotein analysis.
Beyond the standard lipid panel, the AXINON® System provides a more detailed and standardized analysis of the lipoprotein subclasses, via Magnetic Group Signaling (MGS®) technology.
numares AXINON® lipoFIT®-S100 system** measures concentration, size and distribution of lipoprotein particles (which carry cholesterol) and determines the respective quantity of the key compounds triglycerides, cholesterol and phospholipids.
More information on the AXINON® System:
The AXINON® System enables comprehensive lipoprotein analysis and is suited for solid high-throughput operation with minimal hands-on time.
The combination of MGS® and the AXINON® System allows for spectral analysis with highly-reproducible results. The system is easy to use requiring minimal operator interaction. The system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
To date, more than 1.5 million tests have been performed worldwide using numares’ technology.
* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.